Background-Healthy lifestyle changes are thought to mediate cardiovascular disease risk through pathways affecting endothelial function and progression of atherosclerosis; however, the extent, persistence, and clinical significance of molecular change during lifestyle modification are not well known. We examined the effect of a rigorous cardiovascular disease risk reduction program on peripheral blood gene expression profiles in 63 participants and 63 matched controls to characterize molecular responses and identify regulatory pathways important to cardiovascular health. Methods and Results-Dramatic changes in dietary fat intake (−61%; P<0.001 versus controls) and physical fitness (+34%;
C ardiovascular disease (CVD) remains the leading cause of death and healthcare burden in the United States, accounting for 1 of every 3 deaths and ≈$313 billion in healthcare-related costs in 2009. 1 Many patients with coronary artery disease (CAD) require expensive surgical interventions, such as coronary artery bypass grafting or percutaneous catheter placement, with significant morbidity and mortality. 2 
Clinical Perspective on p 160
Abundant research has established the relationship between dietary habits and CVD risk, 3, 4 and physical activity has been associated with significant reductions in cardiac mortality. 5 Lifestyle modification programs focusing on nutrition and exercise have shown substantial health benefits, 6 in part, by improving endothelial function, reducing cardiovascular events, and slowing or reversing progression of coronary atherosclerosis. 7 Although lifestyle programs are effective in mediating CVD risk through traditional risk factors, little is known about molecular change during intensive lifestyle modification or the significance of molecular responses in long-term CVD risk reduction.
We report the effect of an intensive lifestyle program on peripheral blood gene expression to improve our understanding of cellular and molecular changes that occur during risk reduction in patients with, or at risk for, heart disease. Previous studies have shown that patterns of gene expression in peripheral blood are associated with various CVD phenotypes, including presence of CAD 8 and extent of coronary artery atherosclerosis. 9, 10 Our study reveals that gene expression signatures are significantly modulated by rigorous lifestyle behaviors and track with CVD risk profiles over time. These observations suggest that successful and sustained modulation of gene expression through lifestyle changes may have beneficial effects on vascular health that cannot be discerned from traditional risk factor profiles.
Methods

Participants
The research protocol was approved by the Institutional Review Board at Windber Medical Center. All subjects volunteered to participate and gave written informed consent. Men and women willing to make comprehensive lifestyle changes completed a prospective, nonrandomized clinical intervention to stabilize or reverse progression of heart disease through changes in lifestyle. Entry criteria were (1) diagnosis of CAD, which included stable angina, angioplasty, evidence of ≥50% luminal narrowing on coronary angiogram, acute myocardial infarction, bypass surgery, or stent placement; or (2) ≥2 CAD risk factors: hypertension (systolic pressure >140 mm Hg or diastolic pressure >90 mm Hg), high total cholesterol (>200 mg/dL), diabetes mellitus, obesity defined as body mass index (BMI) ≥30, or family history of heart disease in parents or siblings. Controls receiving only standard care from their primary physicians were prospectively matched to program participants based on age, sex, and disease status. 11
Traditional CAD Risk Factors and Diet
Participants were enrolled on an ongoing basis in a lifestyle intervention that consisted of 4 components: (1) low-fat vegetarian diet (<10% of calories from fat), (2) 180 minutes/wk of moderate aerobic exercise, (3) 1 hour of stress management each day, and (4) weekly group support sessions. Demographic and clinical information was obtained by standard questionnaires at baseline, 12 weeks, and 52 weeks. Physiological and biochemical variables were assessed as previously described. 12, 13 Dietary data were collected from self-reported 72-hour dietary recall questionnaires. Food Processor v8.4.0 (ESHA Research) was used to determine daily caloric intake and nutrient composition.
Blood Collection, RNA Preparation, and Microarray Analysis
Peripheral blood was obtained from participants at each time point using the PAXgene Blood RNA System (Qiagen). RNA was isolated and quantified following the Qiagen protocol. Globin mRNA transcripts were depleted from a portion of each total RNA sample using the GLOBINclear-Human kit (Ambion). Globin-depleted RNA aliquots (1 μg) were amplified using the MessageAmp II aRNA Amplification System (Ambion). Resulting double-stranded cDNA was purified, amplified, and labeled with biotin-11-uridine-5ʹtriphosphate. Labeled aRNA (15 μg) was then fragmented and hybridized to GeneChip Human Genome U133A 2.0 arrays (Affymetrix) and scanned on a GeneChip Scanner 3000. Samples were run in batches for globin reduction (n=12), RNA amplification (n=12), and microarray analysis (n=6), keeping all 3 time points for each participant together in the same batch to minimize technical artifact. All gene expression data have been deposited in the Gene Expression Omnibus, series accession number GSE46097 (http://www.ncbi.nlm. nih.gov/geo/query/acc.cgi?acc=GSE46097).
Informatics and Analysis
Statistical analysis of CVD risk factors was conducted using JMP (v9.0). Baseline levels for intervention and matched controls were compared using a matched pairs t test, and change in risk factors over time was assessed with a Wilcoxon signed-rank test, which analyzed differences in risk factor response among the matched pairs.
Partek Genomics Suite v6.5 (Partek Incorporated) was used to analyze gene expression data from the 378 CEL files, which all passed standard quality control assessment. Duplicate blood samples collected at each time point from 7 random participants indicated high repeatability of the microarray data (average Pearson correlation of normalized intensities was 0.992±0.006; range, 0.969-0.996). Paired t tests identified 9 genes that were excluded from further analysis because of significant differences in expression among duplicate samples ( Table I in the Data Supplement) .
Using 1-way analysis of variance with false discovery rate correction for multiple testing, we first compared baseline levels of gene expression between lifestyle participants and controls and then examined expression changes from baseline to week 12 and baseline to week 52 in lifestyle participants, and separately in controls, to determine genes that changed significantly over time in each group. Stringent gene lists were generated through combined significance (FDR P<0.05) and expression change (≥1.1-fold) filtering. Pairwise Pearson productmoment correlations between changes in gene expression and changes in CVD risk factors were calculated using JMP. Functional enrichment analysis was performed on stringent gene lists to identify biological processes controlled by differentially expressed genes. Gene set enrichment analysis, using BRB-ArrayTools v4.2.1 on the Kyoto Encyclopedia of Genes and Genomes database, identified differential expression between groups of genes with common biological function or regulation. 14 To distinguish the effects of the program from the potential influence of medications on gene expression, ancillary analyses were conducted that included only participants who were not taking or did not change the brand or dosage of medications in the following categories: angiotensin-converting enzyme inhibitors, β-blockers, calcium channel blockers, or lipid-lowering drugs.
Transcript Validation by Quantitative Reverse Transcription Polymerase Chain Reaction
Total RNA (500 ng) was reverse transcribed using the High-Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and subjected to quantitative reverse transcription polymerase chain reaction using TaqMan Gene Expression Assays (Applied Biosystems). All target gene expression levels were normalized to the housekeeping gene GAPDH. Samples were run in duplicate for each assay, and the mean value was analyzed by the ΔΔC T method. 15, 16 A repeated measures analysis of variance then determined whether fold-change in expression between time points for each gene was statistically significant. Additional materials and methods are described in the Data Supplement.
Results
The average age of lifestyle participants was 60.3 years (range, 44.5-78.4 years). Many participants entered the program with clinically relevant disorders: 41% had hypertension, 60% were clinically obese, and 54% had high cholesterol. At baseline, participants had higher average BMI (32.6±6.7 versus 28.4±3.9) and triglycerides (187±101 versus 133±73 mg/dL) but lower exercise capacity (24.9±7.4 versus 36.7±11.9 mL per kg per minute) than controls (P<0.01), despite the prospective matching strategy ( Table II in the Data Supplement). Participants who completed the program tended to be older (60.3±9.3 versus 55.3±11.3 years of age) and have higher systolic blood pressure (137±17 versus 131±19 mm Hg) than those who dropped out (P<0.05; Table III in the Data Supplement).
Traditional CAD Risk Factors and Diet
The program resulted in substantial reductions in the number of hypertensive (41% down to 17%), obese (60%-37%), and dyslipidemic (54%-37%) patients. In the first 12 weeks, participants showed dramatic improvement in most dietary and CVD risk factors, but little change occurred in controls (Table 1) . At 52 weeks, participants maintained significantly lower daily fat intake (−60%; P<0.001 compared with matched controls) and higher carbohydrate consumption (+30%; P<0.001 versus matched controls). Improvements in BMI (−9%; P<0.001), triglycerides (−7%; P<0.01), and physical fitness (+38%; P<0.001) remained significant compared with matched nonintervention controls, but systolic blood pressure and lipids showed regression toward pretreatment levels.
Gene Expression
Levels of gene expression were similar between participants and controls at baseline-only 1 (214731_at) of 22 277 probes showed a significant difference (FDR P<0.05) between groups. Stringent differential analysis identified 26 unique genes (3 upregulated and 23 downregulated) that changed significantly in expression after 3 months of intervention (Table IV in the Data Supplement). By 1 year, 143 characterized genes were significantly upregulated (n=44) or downregulated (n=99) from baseline in lifestyle participants ( Table 2 ; Table V in the Data Supplement). Downregulation of gene expression during lifestyle change occurred far more frequently than expected by chance. Using a binomial distribution calculated as a probability mass function with P=0.5, the probability was 3.9×10 −5 for observing 23 of 26 genes downregulated at 12 weeks and 1.4×10 −6 for 99 of 143 genes downregulated at 52 weeks. Validation using quantitative reverse transcription polymerase chain reaction confirmed the overall accuracy of the array-based expression results for the transcripts tested (Table 3 ). In contrast to lifestyle participants, control subjects showed no change in gene expression after 12 weeks (0 genes) and little change by 52 weeks (21 genes; Table VI in the Data Supplement).
Correlations Between CVD Risk Factors and Gene Expression
Throughout the program, many genes exhibiting the largest fold-changes in expression were significantly correlated with BMI ( Figure 1) . Notably, few genes correlated with blood pressure or plasma lipids after 12 weeks. Dysregulation of several genes was associated with improvement in triglycerides (−10%) during the first 3 months but was not associated after the 12-week examination when triglyceride levels regressed toward baseline.
Functional Analysis
Functional enrichment analysis indicated that genes showing significant changes in expression during the intervention function mainly in immune response and cholesterol storage ( Table  VII in the Data Supplement). Genes with the greatest changes in expression at 12 weeks showed regression by 52 weeks (Figure 2 ). Expression of the majority of immune response genes (65%) closely paralleled the substantial improvement followed by regression pattern observed for some traditional risk factors. In contrast, many cholesterol/lipid homeostasis genes (67%) showed a pattern of continual change throughout the program similar to BMI.
Gene set enrichment analysis provided additional insight into molecular pathways regulated by cardiovascular risk factor modification but that were subtle at the individual gene level. Table 4 shows Kyoto Encyclopedia of Genes and Genomes pathways with Efron-Tibshirani max mean statistic 17 ≤0.001 at 12 and 52 weeks. Pathways affected early in lifestyle modification were related to carbohydrate metabolism, glycoprotein hormone levels, and cytokine production, whereas pathways altered later control steroid hormones, cell mobility, and signal transduction and inflammation.
Effects of Medications
Participants were taking 79 different prescription medications at baseline. To determine whether common cardiovascular medications affected gene expression, we examined subgroups of participants based on medication use. In these analyses, changes in expression in participants not taking cardiovascular medications or whose medication levels did not change during the study were similar to changes in all participants, showing that prescription medication use did not have significant effects on gene expression during lifestyle change ( Table 5 ).
Discussion
Participants who completed a comprehensive lifestyle intervention designed to reverse or stabilize progression of CAD dramatically changed their dietary habits and significantly increased physical activity, which led to substantial weight loss during 1 year. We have previously shown that CVD risk reduction through intensive lifestyle change has positive effects on vascular and mental health by reducing cardiometabolic risk, 12 modulating plasma lipoprotein profiles, 13 and improving clinical measures of depression and stress. 18 Here, we show that †Probes were significant at 12 wk. ‡Three probes for TNS1 and GYPB and 2 probes for FECH, HP/HPR, IQGAP, and CDC27 showed a significant fold-change from baseline to 52 wk. §Gene Ontology molecular function.
intensive lifestyle behaviors also modulate gene expression in peripheral blood, suggesting potential CVD risk-reduction mechanisms involving leukocyte function in innate immunity, lipid homeostasis, and inflammation. Lifestyle modification has been shown to be effective in improving clinically relevant CVD risk factors; however, the extent, persistence, and significance of molecular change accompanying CVD risk reduction are not well known. Daily macronutrients can influence short-term changes in genes related to inflammation, carbohydrate metabolism, and immune function, 19 whereas long-term dietary composition may affect genes and pathways regulating development of atherosclerosis and CVD. 20 Similarly, physical activity induces a variety of rapid biophysical and biochemical responses, including altered expression of genes related to oxidative stress, signal transduction, and inflammation. 21, 22 Because expression of diet-and exercise-responsive genes tends to be transient in nature, little is known about the long-term clinical significance of these changes.
During lifestyle modification, participants successfully adopted healthy lifestyle behaviors including a low-fat diet and increased physical activity, which may be important drivers of molecular change. In our analysis of individual genes, immune response and lipid homeostasis were enriched functional categories. The drastic reduction in dietary fat intake during the intervention may influence expression of genes related to lipid storage and transport. Similarly, the predominant downregulation of immune/defense response genes may reflect lower psychological stress and improved vascular health.
B-W52
Single-gene analysis may miss important effects of lifestyle change on complex molecular pathways; therefore, we conducted gene set enrichment analysis to overview biological processes relevant to CVD risk reduction. Pathways significantly altered were related to physiological changes during the program. The gonadotropin-releasing hormone signaling pathway and the androgen and estrogen metabolism pathway †Includes only participants not taking angiotensin-converting enzyme inhibitors, β-blockers, calcium channel blockers, or lipid-lowering medications or whose medication levels for these drugs did not change during the study.
‡Based on a Kruskal-Wallis nonparametric test comparing change in gene expression from baseline to 52 wk among groups. regulate steroid hormones and activate diverse signaling pathways in nonpituitary tissues that modulate gene expression, cell proliferation, and stress response. 23 Because estrogen and androgen levels are commonly elevated in obesity and weight loss can significantly lower serum estrogen and testosterone levels, 24 weight reduction may lead to changes in pathways affecting sex hormones. Similarly, the propanoate metabolism pathway is related to carbohydrate metabolism and glycolysis; thus, functional changes may reflect increased carbohydrate consumption during the program.
The Helicobacter pylori bacterium colonizes the human gastric mucosa and activates multiple signaling pathways. 25 Weight loss through dietary change has been shown to significantly alter the species composition of the intestinal microbiome, 26 thus activation of the H. pylori pathway in the first 12 weeks may reflect changes in gut microbiota because of significant dietary changes. Other pathways involving the actin cytoskeleton and glycosylphosphatidylinositol anchor biosynthesis are related to signal transduction, inflammation, and host-pathogen interactions. 27 Whole blood RNA isolation systems such as PAXgene accurately capture in vivo transcription profiles but cannot distinguish expression signatures unique to specific cell types. To better understand vascular responses to lifestyle modification, we compared genes that were differentially regulated during CVD risk reduction to expression signatures reported for major leukocyte subpopulations. Genes influenced by lifestyle change were expressed in several cell populations, suggesting that different types of circulating cells with unique and specialized functions may be involved in vascular responses to lifestyle modification (Figure 3) .
Neutrophils and T-lymphocytes comprise the most abundant leukocyte populations and play essential roles in inflammation and microbial infection. Genes expressed by these specialized cells were downregulated during lifestyle modification, which provides insight into their vascular function and potential role in mediating cardiovascular risk. In particular, neutrophil lactoferrin (LTF; or lactotransferrin) is a multifunctional glycoprotein that serves an important role in host defense and innate immunity. In the circulatory system, LTF Gene  LTF  TNS1  LCN2  CEACAM8  GYPB  XK  BCL2L1  BPGM  FECH  CRISP3  HP/HPR  OLFM4  IQGAP1  KANK2  RNF10  TRIM10  CAMP  CDC27  AP2B1  BPI  GYPB/GYPE  WNK1  HP  SPTB  TCN1  CLPTM1  DSC2  MMP8  RETN  CEACAM6  MICAL2  MKRN1  SIAH2  CLEC5A  PPP3R1  PSME4  S100A12  ADRBK2  KLHL24  TRAK2  AGFG1  C1orf144  CD36  SP100  ALDH5A1  CTSB  CYP1B1  EZR  GAPVD1  MAP4K5  MTMR3  PAK2  SORT1  CREG1  CTNNA1  DENND1A  FRMD4A  MAPK1  MEGF9  PDLIM5  SCD  STXBP2  ALDH2  CYBB  CYFIP1  DPYSL2  EMR1  HK1  LDLR  MKLN1  PLBD1 CD8+ Gene  TNS3  TPR  ASGR2  CBARA1  CSNK2A1  IRAK3  KIAA0494  PSMD1  TMEM176B  TPM4  C3AR1  C6orf106  FBN2  GAS7  GNA15  KCTD12  LSM12  PLCL2  RALBP1  RRAGD  SLAMF7  SNX3  SRD5A1  TJP2  TMPO  TSPAN4  ATP2A2  DDX6  NBN  TMEM176A  OTUD3  PFN2  TUBG2  C16orf67  EVL  FGF9  FNBP4  IL11RA  LUC7L3  MLL  PHF1  RAB40B  RPL10  RPL37A  TNFRSF25  ZNF248  ANK3  ENO2  FAM153A/B/C  HNRNPL  HOXB2  LOC730092  LPIN1  ME3  NACA  REV1  SFRS17A  SFRS7  TAF1D  ENOSF1  HNRNPH3  LOC150759  PURA  GPRASP1  LOC729799  SIP1  ZDHHC11  RRN3  PTCH1  ZFAND6  ZNF204 CD8+ ║Calvano et al. 32 ; #Xiao et al. 33 released by neutrophils regulates production of reactive oxygen species, recruits immune cells to sites of inflammation, and is positively associated with coronary artery stenosis 34 and risk for fatal ischemic heart disease. 35 LTF gene expression is induced in atherosclerotic plaques of human aortas compared with nonatherosclerotic internal thoracic arteries, 36 and salivary LTF concentrations are 60% lower in elite athletes versus sedentary controls. 37 Importantly, in vitro studies have shown that LTF directly affects leukocyte functions that contribute to CVD, including attenuating leukocyte adhesion to vascular endothelial cells, modulating proinflammatory cytokine expression in endothelial cells, and inhibiting processes essential for vascular dysfunction such as proliferation, migration, and angiogenesis. 38 Such parallel evidence implicating LTF in vascular health increases confidence in the validity of our findings and suggests LTF may be therapeutic in patients with CVD who lead unhealthy lifestyles. Lipocalin-2 (or neutrophil gelatinase-associated lipocalin) is a proinflammatory glycoprotein released by activated neutrophils in response to inflammatory stimuli. 39 Clinical and experimental studies suggest serum lipocalin-2 levels are elevated in obesity and related metabolic complications 40 and positively associated with CAD and cardiac dysfunction. 41, 42 Lipocalin-2 is highly expressed in vascular smooth muscle cells and may function in atherosclerotic plaque development by promoting endothelial activation and vascular leukocyte infiltration. 43 Carcinoembryonic antigen-related cell adhesion molecules are immunoglobulin-related glycoproteins that are glycosylphosphatidylinositol-anchored to the surface of granulocytes (neutrophils and eosinophils), where they regulate activation and release of proinflammatory mediators during inflammation and host immunity. 44 Carcinoembryonic antigen-related cell adhesion molecules have been shown to influence neutrophil adhesion to human umbilical vein endothelial cells. 45 Changes in blood leukocyte gene expression when immune cell function is accentuated, such as systemic inflammation and severe trauma, provide further insight into regulation of leukocyte function during CVD risk reduction. In response to severe bodily injury and infection, leukocytes significantly upregulate expression of numerous genes involved in inflammation and innate immunity. 32, 33 Interestingly, genes showing some of the greatest fold increases in expression during severe trauma (LTF, matrix metallopeptidase 8, and haptoglobin) were significantly downregulated during lifestyle change. Lifestyle modification thus may have beneficial effects on vascular health by reducing expression of proinflammatory genes associated with activation of neutrophil granulocytes.
In this study, we controlled for many covariates known to influence blood-based gene expression profiles, 29, 46 such as age, sex, time of day, and fasting status, through matching and experimental design. Another complicating factor common among patients with CVD is medication use. Many participants entered the program in poor cardiovascular health, with hypertension, obesity, and hyperlipidemia and, as a result, were taking several prescription medications. These medications may affect cellular function and alter patterns of gene expression in peripheral blood, 47 thus confounding the true effects of lifestyle change. Our analysis indicated that common CVD medications did not have significant effects on peripheral blood gene expression and suggest that alterations in individual genes and multigene pathways were attributable to lifestyle changes.
We showed that intensive lifestyle modification can significantly alter the expression of numerous genes associated with leukocyte function, vascular inflammation, and lipid homeostasis. Fold-changes we observed during a 1-year period in patients undergoing lifestyle modification were comparable in magnitude to differences in expression reported for patients with CVD compared with healthy controls. 8, 10 Similar to traditional risk factors, however, these molecular changes seem dynamic, and persistence over time may depend on longterm adherence to healthy behaviors. The number of significantly altered genes increased >5-fold from week 12 to week 52, suggesting that patients who maintain healthy lifestyle behaviors for longer periods of time are likely to experience more diverse molecular change than patients participating in short-term activities. In addition, some conventional risk factors and gene expression profiles showed regression toward baseline after 12 weeks, which corresponded with a lower percentage of participants meeting compliance targets, particularly for exercise and stress management ( Table VIII in the Data Supplement). Adherence to cardiovascular treatment regimens involving lifestyle change is particularly difficult, and many patients usually adhere only partially to programmatic goals. 48 Thus, personal motivation and strict adherence are key factors for successful long-term cardiovascular benefit.
Limitations
Intensive lifestyle programs for CVD risk reduction involve demanding behavioral changes that require motivation and a significant time commitment, which likely restrict the applicability of such programs to patients in general. Accordingly, it was impractical to use a randomized study design, which may limit the conclusions that can be drawn from the data, although well-designed case-control studies may be similar to randomized trials for estimating treatment effects. 49 We analyzed the data using a per-protocol (on-treatment) approach but included all patients who completed the program regardless of whether they strictly adhered to the program guidelines. The multifaceted nature of the program precluded us from precisely defining the relative contribution of each component in driving molecular and physiological changes; however, the correlation analysis indicated that many observed changes in gene expression may be attributable to weight loss and physical activity. Furthermore, we could not evaluate long-term changes in gene expression and CVD risk factors beyond 1 year, and we could not assess whether the observed results are achievable outside a controlled clinical environment.
During the intervention, our patients remained under the care of their primary physicians, who may have prescribed medications other than cardiovascular medications. We conducted a subgroup analysis to account for potential effects of common cardiovascular medications on patterns of gene expression, but it is possible that other medications not examined in these analyses influence leukocyte gene transcription.
Peripheral blood is a complex tissue with diverse cell populations whose relative abundance is dynamic over time. Gene expression studies using whole blood cannot distinguish the effects of cellular demographics from signatures of physiological response. To address this issue, we examined published expression signatures of major leukocyte populations to infer specific cell types involved in response to lifestyle modification; however, rare cell types not examined may play an important role in CVD risk reduction.
Conclusions
CVD prevention through intensive lifestyle changes leads to improvements in clinically relevant cardiac risk factors that may be important in the pathogenesis of atherosclerosis. 50 However, the extent and significance of molecular changes that accompany CVD risk reduction during lifestyle change are poorly understood. There is growing evidence that peripheral blood gene expression reflects the pathophysiology of circulating leukocytes and the vascular endothelium. An increased understanding of dynamic changes in the leukocyte transcriptome during lifestyle modification thus may be crucial for evaluating the efficacy of risk-reduction strategies and understanding mechanisms by which diet and exercise affect cellular processes involved in CVD risk reduction. Conventional risk factors such as low-density lipoprotein cholesterol and blood pressure continue to be primary targets of clinical management for patients with CVD, but as new biochemical and genomic risk factors are identified, it is becoming clear that measures of vascular health go beyond traditional risk factors. A key finding of this study is that successful, sustained modulation and dramatic downregulation of genes, including LTF, through healthy changes in lifestyle may have positive effects on vascular health not readily apparent from traditional risk factors. Future studies are needed to validate changes in gene expression during lifestyle modification and examine the effect of healthy behaviors on leukocyte function and leukocyte-endothelium interactions that are important for cardiovascular health.
